The former baseball star talks about caregiving, loss, and why early detection of idiopathic pulmonary fibrosis (IPF) matters ...
The trial evaluated 213 participants with IPF over a 24-week period across 74 medical centres located in 14 countries.
Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 ...
When examining sphingolipid profiles in patients with idiopathic pulmonary fibrosis and patients with fibrotic ...
Editor's Note: Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause, affecting mostly older adults. Confined to the lungs, the disease causes lung tissue to become thick and scarred over ...
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in ...
Bristol Myers Squibb announced that the admilparant Phase 3 ALOFT-IPF trial in adult patients with idiopathic pulmonary ...
Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung ...
BOSTON--(BUSINESS WIRE)--Celea Therapeutics, Inc. ("Celea" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for serious respiratory diseases ...
AI models suggest IPF is a dysregulation of aging, not just accelerated aging, with unique gene expression patterns. Key pathways in IPF and aging include TGF-β signaling, oxidative stress, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results